Comparing the current results to its competitors, Fate Therapeutics Inc reported Revenue decrease in the 1 quarter 2026 year on year by -20.26 %, despite the revenue increase by the most of its competitors of 4.65 %, recorded in the same quarter.
Fate Therapeutics Inc , slower than the average decrease reported by the company's competitors of -6.5 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -6.5 %
Fate Therapeutics Inc 's Comment on Competition and Industry Peers
The company competes with major pharmaceutical, specialty pharmaceutical, and biotechnology firms, as well as academic institutions, governmental agencies, and public and private research organizations. Its competitors include those developing standard-of-care treatments, new products, and combination therapies such as antibody-based therapies, including bi-specific antibodies. Notable competitors include Novartis AG (Kymriah), Kite Pharma (Yescarta), Bristol-Myers Squibb Company (Breyanzi), Regeneron Pharmaceuticals, Inc., Sana Biotechnology, Inc., and Takeda Pharmaceutical Company Limited. These competitors may possess greater financial, technical, and human resources, along with more experience in product development, regulatory approvals, and commercialization. The company also faces competition in recruiting personnel, establishing clinical study sites, and acquiring complementary technologies. Competition is expected to increase as new products and advanced technologies emerge.
November 8, 2024
Cutting-Edge CAR T-Cell Therapy: Fate Therapeutics’ Breakthrough Data and Stellar Financial Performance Set to Revolutionize Cancer TreatmentIn an era where advancements in immunotherapy are reshaping oncological treatment paradigms, Fate Therapeutics, Inc. has emerged as a frontrunner with the presentation of its preclinical data for its innovative FT836 product candidate. Highlighted at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), FT836 represents a cutting-edge leap in the realm of CAR T-cell therapies. This multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived CAR T-cell product targets specific proteins expressed on cancer cells that are both a product of ...
May 9, 2024
Fate Therapeutics, a leading biopharmaceutical company focused on the development of off-the-shelf cell therapies, recently announced significant advancements in their groundbreaking CAR T-cell programs for the treatment of autoimmune disorders and advanced solid tumors. The company has successfully treated the first Lupus patient in their Phase 1 Autoimmunity Study using the FT819 CAR T-cell program, while also initiating a Phase 1 Clinical Trial for the HER2-expressing advanced solid tumors treatment with FT825/ONO-8250 iPSC-derived CAR T-cell product candidate.In the Phase 1 Autoimmunity Study, Fate Therapeutics demonstrated the efficacy of their off-the-shelf FT819 CAR T-cell program in the treatment of ...
January 8, 2024
San Diego-based biopharmaceutical company Fate Therapeutics, in conjunction with Ono Pharmaceutical Co., recently announced the initiation of a groundbreaking Phase 1 Clinical Trial for cellular immunotherapy FT825/ONO-8250 in patients battling HER2-expressing advanced solid tumors. Encompassing a novel HER2-targeted antigen-binding domain, this innovative product candidate originates from induced pluripotent stem cells (iPSCs).Fate Therapeutics, notable for its transformative work in cell-based cancer immunotherapy, is incorporating an unprecedented seven synthetic controls of cell function into FT825/ONO-8250 in its pursuit of pioneering novel treatments. HER2 (human epidermal growth factor receptor 2) is ...
MeiraGTx Holdings Plc is a biotechnology company focused on developing gene therapies for inherited and acquired diseases. They leverage their proprietary technology to develop and commercialize innovative treatments that address unmet medical needs.
Molecular Partners Ag is a biotechnology company that operates on an innovative business model focused on the development of therapeutic drugs. The company utilizes its proprietary DARPin technology platform to create a pipeline of potential treatments for various diseases. Molecular Partners Ag primarily collaborates with strategic partners, including pharmaceutical companies, to advance its drug candidates through preclinical and clinical development stages.
Marker Therapeutics Inc is a biotechnology company that aims to develop and commercialize novel T cell immunotherapies for the treatment of cancer. Their business model focuses on leveraging their expertise in cellular engineering to develop proprietary technologies and therapies that can be licensed or partnered with other organizations for further development and commercialization.
Merus N V is a biotechnology company that operates using a differentiated and competitive business model. Their approach involves strategically targeting and developing bispecific antibodies to treat various types of cancer, leveraging their proprietary technologies and expertise in the field. By focusing on innovative research, efficient drug discovery, and partnerships, they aim to improve patient outcomes and drive growth in the oncology market.
Sources:
Fate Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Fate Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
